CRIS Current Research Information System

RICCIUTI, BIAGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.430
NA - Nord America 1.334
EU - Europa 578
SA - Sud America 162
AF - Africa 52
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.562
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 1.335
US - Stati Uniti d'America 1.279
SG - Singapore 715
CN - Cina 662
HK - Hong Kong 257
IT - Italia 202
BR - Brasile 125
BD - Bangladesh 117
KR - Corea 107
IN - India 79
NL - Olanda 64
DE - Germania 59
FI - Finlandia 44
IE - Irlanda 36
FR - Francia 32
JP - Giappone 28
CA - Canada 25
SE - Svezia 25
BG - Bulgaria 23
JO - Giordania 22
MX - Messico 21
AR - Argentina 20
TH - Thailandia 20
RU - Federazione Russa 19
AT - Austria 18
ID - Indonesia 18
GB - Regno Unito 16
PH - Filippine 15
CI - Costa d'Avorio 11
PK - Pakistan 10
IQ - Iraq 9
CH - Svizzera 8
TG - Togo 7
TR - Turchia 7
BE - Belgio 6
PL - Polonia 6
ZA - Sudafrica 6
AU - Australia 5
LT - Lituania 5
VE - Venezuela 5
CL - Cile 4
EG - Egitto 4
JM - Giamaica 4
MA - Marocco 4
SC - Seychelles 4
TN - Tunisia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
GR - Grecia 3
IL - Israele 3
KE - Kenya 3
MY - Malesia 3
PT - Portogallo 3
UZ - Uzbekistan 3
CR - Costa Rica 2
DZ - Algeria 2
EC - Ecuador 2
ES - Italia 2
NI - Nicaragua 2
NP - Nepal 2
OM - Oman 2
PY - Paraguay 2
SA - Arabia Saudita 2
SN - Senegal 2
UY - Uruguay 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
KZ - Kazakistan 1
LB - Libano 1
LY - Libia 1
MK - Macedonia 1
ML - Mali 1
MN - Mongolia 1
NG - Nigeria 1
PE - Perù 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.562
Salva come PNG Salva come JPEG
Città #
Singapore 468
Ho Chi Minh City 424
Hanoi 314
Hong Kong 251
Hefei 217
Ashburn 205
San Jose 171
Santa Clara 164
Seoul 97
Beijing 81
Boardman 63
Bologna 53
Da Nang 44
Haiphong 41
Helsinki 41
Dublin 36
Los Angeles 36
New York 36
Council Bluffs 35
Quận Bình Thạnh 32
Hyderabad 30
Buffalo 29
Ninh Bình 24
Biên Hòa 23
Sofia 23
Tokyo 23
São Paulo 21
Thái Nguyên 21
Amman 20
Bengaluru 20
Dallas 20
Ha Long 19
Lauterbourg 19
Nuremberg 17
Can Tho 16
Hải Dương 16
Rome 16
Shanghai 15
Chicago 14
Falkenstein 14
Milan 14
Chandler 13
Redondo Beach 13
Bắc Ninh 12
Orem 12
Seattle 12
Abidjan 11
Frankfurt am Main 11
Guangzhou 11
Jakarta 11
Mexico City 11
San Francisco 11
Thành Phố Bà Rịa 11
Vinh 11
Quận Phú Nhuận 10
Vũng Tàu 10
Điện Bàn 10
Bắc Giang 9
Vienna 9
Thái Bình 8
Tongling 8
Atlanta 7
Bangkok 7
Cà Mau 7
Lomé 7
Quảng Ngãi 7
Quận Bốn 7
Toronto 7
Wuhan 7
Zhengzhou 7
Bern 6
Brooklyn 6
Hòa Bình 6
Modena 6
Montreal 6
Nam Định 6
Nanjing 6
Naples 6
Nha Trang 6
Quận Một 6
San Antonio 6
Turin 6
Uyen Hung 6
Valdagno di Trento 6
Verona 6
Amsterdam 5
Brasília 5
Chengdu 5
Foshan 5
Mumbai 5
Phủ Lý 5
Quận Bảy 5
Rimini 5
Shenzhen 5
The Dalles 5
Tianjin 5
Tuy Hoa 5
Việt Trì 5
Yubileyny 5
Baghdad 4
Totale 3.664
Salva come PNG Salva come JPEG
Nome #
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 928
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 219
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status 172
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 158
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels 155
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 154
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 147
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease 145
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 135
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks 131
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 121
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC 118
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 115
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 113
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 109
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 105
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 103
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 88
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 87
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 84
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 84
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 82
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 80
Non-small-cell lung cancer: how to manage RET-positive disease 79
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 74
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy 73
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS) 70
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 70
Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis 69
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 67
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 67
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 65
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 64
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 63
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 63
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 62
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 59
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience 59
Non-small-cell lung cancer: how to manage EGFR-mutated disease 58
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 57
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities 53
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC 53
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation 53
Antibody–drug conjugates for lung cancer in the era of personalized oncology 52
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 49
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer 48
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 48
Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient 46
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 44
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 42
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 41
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 41
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 40
Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC 39
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) 39
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort 39
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC 38
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 37
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 36
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 35
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer 35
Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer 32
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 23
Totale 5.715
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.649
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202214 0 0 0 0 0 0 0 4 0 2 5 3
2022/2023204 3 8 0 9 7 4 3 14 73 34 20 29
2023/2024195 12 17 19 16 15 39 7 44 9 7 4 6
2024/20251.255 32 98 96 63 230 66 127 45 13 88 99 298
2025/20263.931 1.191 374 251 217 243 135 251 131 462 256 216 204
2026/2027116 116 0 0 0 0 0 0 0 0 0 0 0
Totale 5.715